Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.40 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.40 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1692212 | 0.77 | CRBN (0.44) | METMAPK10DYRK1BKCNH2CLK1 | |
| SCHEMBL1692304 | 0.77 | DYRK1B (0.40) | METMAPK10DYRK1BKCNH2CLK1 | |
| SCHEMBL1702652 | 0.68 | HPGD (0.47) | MAPK10KIF11DYRK1BCLK1DYRK1A | |
| SCHEMBL327502 | 0.67 | MAP2K4 (0.41) | DYRK1BCLK1DYRK1ADYRK2PIP4K2A | |
| SCHEMBL327582 | 0.66 | HSD17B1 (0.42) | MAPK10KIF11DYRK1BCLK1DYRK1A | |
| SCHEMBL1692414 | 0.66 | SCN9A (0.38) | KIF11PIK3CDDYRK1APIP4K2APIP4K2B | |
| SCHEMBL31041151 | 0.66 | KIF11 (0.79) | KIF11DYRK1A | |
| SCHEMBL27934253 | 0.66 | MAP4K4 (0.53) | MAPK10KIF11PIK3CBDYRK1BCLK1 | |
| SCHEMBL3765367 | 0.65 | MAPK10 (0.44) | METMAPK10KIF11DYRK1BCLK1 | |
| SCHEMBL3662656 | 0.65 | PIK3CG (0.77) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590960-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | disclosed |
| US-8329712-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RNASE1 | MET 2762/4885MAPK10 3408/4885KIF11 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.